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Abstract Thyroglobulin (Tg) proteolytic steps are central 
phenomena in Tg processing and thyroid hormone release in 
thyrocytes. Based on recent literature data, we propose that the 
type-I repetitive units present in the Tg sequence could act as 
binders and reversible inhibitors of the proteases implicated in Tg 
processing. The pH-dependent interactions of proteases with the 
repeats could permit (i) protection from degradation of low 
iodinated Tg to be recycled; (ii) restriction of early proteolytic 
attacks to N- and C-terminal hormone formation sites; (iii) 
increase of the half-time of acidic proteases necessary for the 
final, extensive degradation steps of Tg. 
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1. Introduction 
Thyroglobulin (Tg) is the precursor of the thyroid hor- 
mones 3,3',5-triiodo-L-thyronine (T3) and L-thyroxine (T4). 
Tg synthesis occurs exclusively in the epithelial cells (thyro- 
cytes) of the thyroid gland and is stored in the lumen of 
thyroid follicles. There, iodination and intramolecular cou- 
pling of tyrosine residues from Tg take place. T3 and T4 
secretion involves internalization, sorting of the most iodi- 
nated Tg molecule, and transport o lysosomes [1,2]. The 
thyroid hormone residues are released by early and limited 
alteration of the Tg structure [3]. Intensive Tg degradation 
is a delayed process, requiring several hours [4]. In spite of 
numerous reports on Tg proteolytic attacks by thyroid pro- 
teases [5-9], the physiological mechanisms for selective hor- 
mone release and sequential processing remain unclear. The 
amino acid sequence of Tg [10,11] encloses three kinds of 
cysteine-rich repetitive regions. In particular, there are 11 N- 
terminal repetitive sequences, which we recently characterized 
as Tg type-1 modules [12]. The function of these repetitive 
sequences in Tg is at present unknown. Tg type-1 modules 
were identified in 32 proteins belonging to seven different 
families. The different biological functions performed by these 
proteins apparently do not directly implicate their Tg type-1 
modules [12], except in one case (see below). In a recent re- 
port, Yamashita and Konagaya [13] reported the isolation 
from chum salmon eggs of a 74 residue protein with extremely 
high sequence similarity with the Tg type-1 module. This pro- 
tein is a cysteine protease inhibitor. This observation and two 
others to be described later have led us to hypothesize that the 
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11 Tg type-1 repeats could function as binders and reversible 
inhibitors of the proteases involved in the proteolytic proces- 
sing of Tg. 
2. The facts: Tg type-1 modules can interact with some 
proteases 
2.1. ECI is a Tg type-1 module which inhibits papain and chum 
salmon cathepsin B 
ECI is one of three isoforms of cysteine protease inhibitors 
found in churn salmon eggs [13]. The sequence of this newly 
isolated small molecule (74 amino acids) is the same as the Tg 
type-1 consensus equence [12] except for an additional 10 
residue N-terminal segment. ECI was found to display specific 
inhibitory activities against papain and chum salmon cathe- 
psin B but not against m-calpain, bovine trypsin, or bovine 
chymotrypsin [13]. Thus, a protein which is extremely similar 
in its sequence to a repetitive unit of thyroglobulin functions 
as a specific protease inhibitor. 
2.2. Cathepsin L is reversibly complexed and inhibited by the 
Tg type-1 module of Ii 
Ii is a transmembrane glycoprotein associated with major 
histocompatibility complex (MHC) class II proteins that exists 
in two alternatively spliced forms, P31 and P41. The addi- 
tional exon of the P41 form codes for a Tg type-1 module 
[14]. Both P31 and P41 seem to be functionally equivalent in 
most of their biological functions (MHC class II chaperone, 
targeting/retention signals, interference with peptide loading 
in the class II molecule [15]). There is only a slight difference 
between P31 and P41 in enhancing antigen presentation which 
is probably due to subtle differences in their proteolytic pro- 
cessing [16,17]. Two facts argue for a possible role of the Tg 
type-1 module in Ii degradation mechanisms. First, Ogrinc et 
al. [18] showed that the C-terminal part of P41 (containing the 
Tg type-1 module) is able to reversibly and specifically inhibit 
and stabilize cathepsin L in a pH-dependent manner; second, 
Fineschi et al. [19] proved that P31 and P41 have different 
patterns of proteolytic processing. Therefore, in transfected 
cells expressing only the P41 form of Ii, degradation of P41 
generates a 12 kDa N-terminal fragment of Ii (P12) that re- 
mains associated with MHC class II for an extended time; in 
contrast, when P31 is expressed alone it is subjected to exten- 
sive degradation without an intermediate fragment associated 
with MHC class II. In cells expressing simultaneously both 
forms of Ii, P31 degradation also generates P12. To explain 
this differential sensitivity to proteases, the authors offered 
two possibilities: either the C-terminus (containing the Tg 
type-1 module) of P41 induces conformational changes which 
0014-5793196l$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
PIISO0 1 4-5793(96)00708-9 
230 F. Molina et al./FEBS Letters 391 (1996) 229-231 
could alter the configuration of protease-sensitive sites, or 
released P41-specific fragments directly change the specificity 
or efficiency of endosomal proteases. These results how that a 
protein containing a Tg type-1 module is both capable of 
binding a protease [18] and of specifically controlling some 
of the proteolytic events that the protein containing the mod- 
ule undergoes [19]. 
2.3. IBP-3 acts as a reversible inhibitor o f  lBP-4 proteolysis 
Insulin-like growth factor binding proteins (IBP) bind in- 
sulin-like growth factor I (IGF I) and modulate the interac- 
tion between IGF I and IGF I receptor [20]. This modulation 
is dependent on different biochemical events comprising pro- 
teolysis of IBP. The sequence of IBP-3 contains a Tg type-1 
module. Fowlkes et al. [21] showed that IBP-3 functions as a 
reversible inhibitor of IBP-4 proteolysis. The protease seems 
to be cation-dependent and is inhibited by a synthetic peptide 
contained in the sequence of the Tg type-1 module. Thus the 
amino acid sequence of the Tg type-1 repeat from IBP-3 is 
endowed with the capacity to inhibit the cation-dependent 
protease activity that contributes to the degradation of IBP-4. 
All these recent experimental data indicate again that some 
Tg type-1 modules have reversible binding and/or inhibitory 
properties for proteases and/or could interfere with the pro- 
teolysis of the protein which contains these modules. Due to 
sequence variations of Tg type-1 modules, it is possible that 
each of the Tg type-1 repeats could be specific for one type of 
protease, which may explain why Yamashita and Konagaya 
[13] did not find any inhibitory activity of Tg against papain, 
which is not present in thyrocytes. 
3. The hypothesis: The Tg type-1 modules of thyroglobulin 
control the sequential proteolytic events of thyroglobulin 
degradation 
The arguments mentioned above raise the possibility that 
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Fig. 1. Upper panel: Schematic drawing of Tg processing in thyro- 
cytes; steps A-E correspond to those described in Fig. 2. Lower 
panel: Major sites of cleavage of rabbit Tg by cathepsins B, H, L 
from human thyrocytes. 
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Fig. 2. Schematic representation f the hypothetic proteolytic proc- 
essing of Tg. 
the 11 Tg type-1 repeats in Tg itself could control the activ- 
ities of the proteases involved in its degradation. Indeed sev- 
eral of the molecular mechanisms of the sequential proteolytic 
processing of Tg remain obscure. In brief, in the first step 
after endocytosis, hormone-containing T is transferred to 
lysosomes where it undergoes rapid (few minutes) and specific 
proteolytic leavage that selectively generates free thyroid hor- 
mones (Fig. 1, upper panel, steps A, B, C). Incompletely io- 
dinated Tg goes back into the lumen for recycling without 
degradation [22]. In a late and long (1-4 h) second step 
(Fig. 1, upper panel, steps D and E) the remainder of the 
Tg molecule is extensively degraded to small fragments and/ 
or amino acids [3]. 
Our hypothesis i as follows. The hormone-containing Tg is 
internalized in endocytotic vesicles. The fusion between these 
Tg-containing endocytic vesicles and primary lysosomes forms 
the thyroid lysosomes [23] where proteases and peptidases 
required for Tg processing are present. The evolution of early 
thyroid lysosomes to late thyroid lysosomes [24] is marked by 
progressive acidification. We propose that using the pH gra- 
dient as a signal, one or several Tg type-1 modules pecifically 
and reversibly bind and inhibit some of the proteases and thus 
regulate the proteolytic activities in the thyroid lysosomes. 
Due to the sequence variation in the Tg type-1 repeats, it is 
possible that the 11 copies in Tg may have specificities for 
different proteases activities. In step A (Fig. 2), hormone-con- 
taining Tg (shown as a monomer for clarity) in endocytic 
vesicles is naked, ready to meet lysosomal proteases (espe- 
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cially cathepsins [5-9]). In step B, a few minutes later, early 
thyroid lysosomes are formed. Some or all of the 11 Tg type-1 
modules bind and inhibit one or more (membrane-associated 
or not) of the cathepsins. The Tg-associated cathepsins are 
thus inhibited and stabilized, so as to increase their half-life, 
and remain available for the late degradation steps. In addi- 
tion, the immature incompletely iodinated Tg could be more 
resistant to degradation i  its way back for recycling in the 
lumen [22]. The drawing in Fig. 1 (lower panel) shows the sites 
of proteolytic leavage of rabbit Tg by cathepsin B, D, L [9]. 
All type-1 repeats, except one, are insensitive to cathepsin 
action. This could be consistent with protection from proteo- 
lysis by the inactivated masking proteases. The unprotected 
parts of Tg, in particular the N- and C-termini, are, however, 
available to attack by other free and active proteases. This is 
consistent with the observation that N-terminal and C-term- 
inal hormone-containing extremities of Tg are cleaved in these 
early stages [3], In step C (Fig. 2), the progressive pH decrease 
could specifically induce the release of a protease specific for 
C-terminal cleavage of Tg from a Tg type-1 repeat. This could 
explain the observation that, in mouse macrophages, T3 re- 
lease occurs later than T4 release, in more acidic compart- 
ments [4], and may be due to the action of different enzymes 
[8]. In step D, the very acidic conditions in the late lysosomes 
constitute the signal for the extensive Tg degradation. The 
release of a second wave of proteases then occurs under opti- 
mal acidic conditions (during this step disulfide bond reduc- 
tion should occur. Our hypothetical Tg degradation mechan- 
ism does not explain the nature of the reduction of disulfide 
bridges. As of now, the reducing agent is still unknown but a 
high concentration of free cysteine in the late lysosomes is 
thought to play this role [3]). The complete degradation of 
Tg (step E) takes a long time (up to 3 h). Since Tg type-1 
modules are probably more resistant o proteolytic attacks 
[25], they could also participate, as proteolytic fragments, in 
the control of an equilibrium between free active proteases 
and inactive bound proteases. In any case, the final step will 
be the extensive Tg degradation with or without Tg type-1 
module recycling. 
4. Conclusion 
Several recent findings in the literature indicate that Tg 
type-1 repeats could have a common function. A Tg type-1 
repeat could act as an internal, selective and reversible pro- 
tease inhibitor included in the protein sequence of various 
proteins. 
In this report we propose a new hypothesis which could 
enlighten our understanding of how proteolytic events lead 
first to selective release of thyroid hormones and then to com- 
plete Tg degradation. These proteolytic events are key steps in 
the single known function of Tg: the release of T3 and T4 
hormones. These proteolytic events must be regulated to par- 
ticipate in a concerted processing. We propose that the 11 
type-1 repeats from Tg could drive this regulation in thyro- 
cytes by selectively and reversibly inhibiting endosomal and/or 
lysosomal proteases following the gradual pH decrease (Fig. 
2) which characterizes lysosomes evolution, Indeed, Tg type-1 
repeat interactions with proteases could permit (i) protection 
from degradation of low iodinated Tg to be recycled, (ii) re- 
striction of early proteolysis to N- and C-terminal hormone 
formation sites, (iii) increase of the half-life of acidic proteases 
necessary for extensive, final, degradation steps, The role we 
tentatively assign to the 11 type-1 repeats of Tg (which to- 
gether correspond to almost half of the amino acid sequence 
of Tg) allows us to understand why molecular evolution has 
conserved such a giant gene coding for a 2748 amino acid 
protein as a precursor of very small hormones. 
Our hypothesis could help us understand the role of the Tg 
type-1 module present in numerous proteins. 
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